New cocktail targets tough leukemia mutations
NCT ID NCT06313437
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called revumenib alongside standard chemotherapy and another targeted drug (midostaurin) for adults newly diagnosed with acute myeloid leukemia (AML) that has specific genetic changes (NPM1 and FLT3 mutations). The study aims to find a safe and effective dose of revumenib in this combination. About 22 participants will receive the treatment to see how well they tolerate it and whether it leads to remission.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Revumenib (a menin inhibitor) combined with standard chemotherapy (cytarabine and daunorubicin) and midostaurin
What this could lead to
If it works, this could point toward a more effective initial treatment for people with certain genetic types of AML, potentially improving remission rates.
What could go wrong
This is a very early Phase 1 trial with only 22 participants, so the main goal is safety and dosing—not yet proof of effectiveness. Side effects from the drug combination are unknown and could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06150, United States
Contact Email: •••••@•••••